Related Experiment Videos
Ipecac administration in children younger than 1 year of age
Insights
Ipecac syrup effectively induces vomiting in infants aged 6-11 months. This study supports its safe home administration for poisoning cases, reducing delays and costs associated with emergency department visits.
Area of Science:
- Pediatric Toxicology
- Emergency Medicine
- Pharmacology
Background:
- Ipecac syrup has been used for inducing emesis in poison-exposed individuals.
- Its safety and efficacy in infants aged 6-11 months require specific evaluation.
- Comparison with older children is essential to understand age-related differences.
Purpose of the Study:
- To evaluate the efficacy and safety of ipecac syrup for inducing emesis in infants aged 6-11 months.
- To compare the outcomes in this age group with older children (12-35 months).
- To assess the impact of ipecac syrup availability on administration time and recommend optimal administration settings.
Main Methods:
- Prospective study comparing 105 poison-exposed infants (6-11 months) with 302 age-matched controls (12-35 months).
- Data collected on emesis induction, side effects, and medical complications.
- Analysis of administration time based on ipecac syrup availability (home, pharmacy, emergency department).
Main Results:
- Ipecac syrup successfully induced emesis in 96.2% of infants (101 out of 105).
- Failure rates and side effect frequencies were comparable between infants and older children.
- No serious medical complications were reported.
- Delayed administration occurred when ipecac syrup was not readily available at home, with longer delays from pharmacies and emergency departments.
Conclusions:
- Ipecac syrup is an effective and safe emetic agent for home administration in infants aged 6-11 months.
- Home administration is preferable to emergency department procurement due to significant time delays.
- These findings support current guidelines for the use of ipecac syrup in pediatric poisoning management.
Abstract:
The efficacy of ipecac syrup in the induction of emesis and safety of its administration was studied in 105 poison-exposed infants 6 through 11 months of age (study subjects) and compared prospectively with 302 poison-exposed infants and children 12 through 35 months of age who served as age controls. Of the 105 study subjects 101 (96.2%) vomited. The failure of ipecac to induce emesis in six patients (four of 105 study subjects two of 302 age control subjects) is comparable with ipecac failure rates reported elsewhere. The frequency of side effects caused by ipecac syrup did not differ between study and control subjects. There were no serious medical complications resulting from the administration of ipecac syrup. When not readily available at home, ipecac administration was delayed an additional 21.8 minutes if obtained from a pharmacy and 38.4 minutes if obtained from an emergency department. Because of the time delay and the increased health care cost, home rather than emergency department administration of ipecac should be advised. These data demonstrate that ipecac syrup effectively induces emesis and is safe for home administration to poisoned infants 6 to 11 months old.